The use of antimicrobial agents in children with fever during chemotherapy-induced neutropenia: The importance of risk stratification

Pediatric Infectious Disease Journal

Volumn 30, Issue 10, 2011, Pages 887-890

  Palazzi, Debra L ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

antimicrobial agents; cancer; fever; neutropenia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CASPOFUNGIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; FLUCONAZOLE; ITRACONAZOLE; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN; VORICONAZOLE;

ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; CANDIDIASIS; CATHETER INFECTION; CHEMOTHERAPY INDUCED NEUTROPENI; CHILDHOOD DISEASE; ENTEROBACTERIACEAE; FEBRILE NEUTROPENIA; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; MEDICAL HISTORY; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; RISK; RISK ASSESSMENT; STAPHYLOCOCCUS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 80052929783     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182311343     Document Type: Review

References (35)

1. Freifeld AG, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2011;52: e56-e93.
2. Walsh TJ, et al. Infectious complications in pe-diatric cancer patients. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:1269-1329.
3. Paganini HR, et al. A prospective, multicentric scoring system to predict mortality in febrile neutropenic children with cancer. Cancer. 2007; 109:2572-2579. (Pubitemid 46906478)
4. Santolaya ME, et al. Admission clinical and laboratory factors associated with death - during a febrile neutropenic episode. Pediatr Infect Dis J. 2007;26:794-798. (Pubitemid 47329849)
5. Castagnola E, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children. Clin Infect Dis. 2007;45:1296-1304.
6. Badiei Z, et al. Risk factors associated with life-threatening infections in children with febrile neutropenia - J Pediatr Hematol Oncol. 2011; 33:e9-e12.
7. Bakhshi S, et al. Infections in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2008;25:385-392.
8. Klastersky J, et al. Bacteraemia in febrile neutro-penic cancer patients. Int J Antimicrob Agents. 2007;30(suppl 1):S51-S59.
9. Baorto EP, et al. Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients. Cancer. 2001;92:909-913. (Pubitemid 32783080)
10. Wicki S, et al. Risk prediction of fever in neutro-penia in children with cancer. Pediatr Blood Cancer. 2008;51:778-783.
11. Agyeman P, et al. Predicting bacteremia in children with cancer and fever in. neutropenia. Pedi-atr Infect Dis J. 2011;30:e114-e119.
12. Greenberg D, et al. Microbiological spectrum and susceptibility of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients -. Int J Antimicrob Agents. 2005;25:469-473.
13. El-Mahallawy HA, et al. Antibiotic resistance is associated with - worse outcome in febrile neu-tropenic children with cancer. Pediatr Blood Cancer. 2011;57:283-288.
14. Danilatou V, et al. Three cases of viridans group streptococcal bacteremia in children with febrile neutropenia. Scand J Infect Dis. 2003;35:873-876. (Pubitemid 38028926)
15. Castagnola E, et al. Fungal infections in children with cancer. Pediatr Infect Dis J. 2006;25:634-639.
16. Villarroel M, et al. Risk factors associated with invasive fungal disease in children with cancer and febrile neutropenia. Pediatr Infect Dis J. 2010;29:816-821.
17. Santolaya ME, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neu-tropenia and fever. J Clin Oncol. 2001;19:3415-3421. (Pubitemid 32642195)
18. Santolaya ME, et al. Prospective evaluation of - prediction of invasive bacterial infection risk among children with cancer, fever and neutrope-nia. Clin Infect Dis. 2002;35:678-683. (Pubitemid 35024727)
19. Hakim H, et al. Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J. 2010;29:53-59.
20. Klaassen RJ, et al. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol. 2000;18:1012-1019. (Pubitemid 30123777)
21. Paul M, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev. 2003:CD003038.
22. Uygun V, et al. Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric - neutropenia and fever -. Pediatr Blood Cancer. 2009;53:610-614.
23. Simon A, et al. Piperacillin-tazobactam in pedi-atric cancer patients. Eur J Clin Microbiol Infect Dis. 2007;26:801-806.
24. Corapcioglu F, et al. Monotherapy with pipera-cillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia. Pediatr Hematol Oncol. 2006;23:177-186.
25. Viscoli C, et al. Piperacillin-tazobactam mono-therapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect. 2006;12:212-216. (Pubitemid 43379320)
26. Paul M, et al. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutro-penia. Cochrane Database Syst Rev. 2010;11: CD005197.
27. Paul M, et al. Additional anti-gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev. 2005: CD003914.
28. Vidal L, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev. 2004: CD003992.
29. Gupta A, et al. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin. J Pe-diatr Hematol Oncol. 2009;31:635-641.
30. Paganini H, et al. Outpatient, sequential, paren-teral-oral antibiotic therapy for lower risk febrile neutropenia in children. Cancer. 2003;97:1775-1780.
31. Quezada G, et al. Medical and non-medical barriers to outpatient treatment of fever and neutropenia in children with cancer. Pediatr Blood Cancer. 2007;48:273-277. (Pubitemid 46238516)
32. Wiley JM, et al. Efficacy and safety of ampho-tericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J. 2005;24:167-174. (Pubitemid 40250777)
33. Maertens JA, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empirical therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J. 2010;29: 415-420.
34. Blyth CC, et al. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev. 2010:CD0006343.
35. Segal BH, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients. Clin Infect Dis. 2007;44:402-409.